Docket No.: 401.1013US
(PATENT)

OK enter
10/1/09

/CC/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Sugasawa, *et al.*

Application No.: 10/500,964 Confirmation No.: 3433

Filed: July 8, 2004 Art Unit: 1625

For: 2-Acylaminothiazole Derivative Or Salt Thereof Examiner: Celia C. Chang

AMENDMENT AND RESPONSE TO OFFICE ACTION

MS: AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 21, 2009

Dear Sir:

In response to the Final Office action mailed on June 30, 2009 please amend the above-identified patent application as follows.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of the claims.

Claims 1-36. (Cancelled)

Claim 37. (Previously Presented) A 2-acylaminothiazole derivative compound represented by the following Formula (V), or a pharmaceutically acceptable salt thereof:



(V)

wherein the symbols have the following meanings:

Ar^2: substituted or unsubstituted phenyl or monocyclic aromatic heterocycle;

R^3: a substituted or unsubstituted thienyl;

R^4: a group represented by Formula II:



(II)

wherein X is $C(R^{27})R^{28}$ or NR^{26} and m=n=2;

wherein $CR^{20}R^{21}$ and $CR^{22}R^{23}$ can be identical or different; and

wherein each of R^{20}, R^{21}, R^{22}, R^{23}, R^{26}, R^{27}, and R^{28} can be the same or different and can be selected from the group consisting of –H; -OH; -O-lower alkyl; a substituted or unsubstituted lower alkyl; a substituted or unsubstituted cycloalkyl; a substituted or unsubstituted aryl; a substituted or unsubstituted arylalkyl; a substituted or unsubstituted aromatic heterocycle; a substituted or unsubstituted aromatic heterocyclic alkyl; a substituted or unsubstituted nonaromatic heterocycle; lower alkenyl; lower alkylidene; -COOH; -COO-lower alkyl; -COO-lower alkenyl; -COO-lower alkylene-aryl; -COO-lower alkylene-aromatic heterocycle; carbamoyl or amino, each of which can be substituted with one or more groups selected from the group consisting of lower alkyl

which can be substituted with halogen, -OH, -O-lower alkyl, or -O-aryl; -NHCO-lower alkyl; and oxo.

Claim 38. (Previously Presented) The compound according to claim 37, wherein Ar^2 is phenyl or pyridyl, each of which can be substituted.

Claim 39. (Previously Presented) The compound according to claim 37, wherein R^3 is a thienyl which is substituted with 1 to 3 halogen atoms, which can be identical or different.

Claim 40. (Currently Amended) The compound according to claim 39[[37]], wherein R^4 is 4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl, 4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

Claim 41. (Currently Amended) The compound according to claim 40[[37]], wherein Ar^2 is phenyl which is unsubstituted at 2- and 6-positions, substituted with -H, -F, -Cl, or -Br at 3-position, substituted with -F, -Cl, or -Br at 5-position, and substituted at 4-position; or pyridin-3-yl which is unsubstituted at 2- and 4-positions, substituted with -F, -Cl, or -Br at 5-position, and substituted at 6-position.

Claim 42. (Currently Amended) The compound according to claim 41[[37]], wherein Ar^2 is phenyl which is substituted at 4-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, a substituted or unsubstituted piperidin-1-yl and a substituted or unsubstituted piperazin-1-yl; or pyridin-3-yl which is substituted at 6-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, a substituted or unsubstituted piperidin-1-yl and a substituted or unsubstituted piperazin-1-yl, wherein R^Y is lower alkyl which can be substituted with one or more groups selected from the group consisting of -OH, -O-lower alkyl, amino which can be substituted with one or two lower alkyl, -CO_2H, -CO-lower alkyl, carbamoyl which can be substituted with one or two lower alkyl, cyano, aryl, aromatic heterocycle, nonaromatic heterocycle and halogen.

Claim ~~43~~ 7. (Currently Amended) The compound according to any one of claims [[~~5, 25 and~~]] ~~37-42~~ 1-6 wherein the pharmaceutically acceptable salt is a maleate salt.

Claim ~~44~~ 10. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of any one of the pharmaceutical compounds of claims ~~37-42~~ 1-6 ~~5, 7, 9-13 and 18-42~~ and a pharmaceutically acceptable carrier.

Claim ~~45~~ 11. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim ~~43~~ 7 and a pharmaceutically acceptable carrier.

Claim ~~46~~ 12. (Previously Presented) The pharmaceutical composition according to claim ~~44~~ 10, wherein the pharmaceutical composition is formulated for oral administration.

Claim ~~47~~ 13. (Previously Presented) The pharmaceutical composition according to claim ~~45~~ 11, wherein the pharmaceutical composition is formulated for oral administration.

Claim ~~48~~ 14. (New) A pharmaceutical composition for treating thrombocytopenia, the composition comprising: a therapeutically effective amount of a compound selected from the group consisting of



and pharmaceutically acceptable salts thereof; and

a pharmaceutically acceptable carrier.

Claim 49. (New) The pharmaceutical composition of claim 48, wherein the compound is:



Claim 50 (New) A compound selected from the group consisting of: 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid, and pharmaceutically acceptable salts thereof.

Claim 51. (New) The compound of claim 51, wherein the pharmaceutically acceptable salt is the maleic acid salt.